Abstract
Introduction: Methotrexate (MTX) is a valuable treatment for psoriasis. Guidelines recommend monitoring liver function tests (LFTs) every 1-3 months, although liver biopsy remains gold standard. Two novel tests, the Fibrosis-4 (Fib-4) score and Fibroscan, have been introduced to assess liver fibrosis noninvasively. This study highlights use of these tools in identifying patients treated with MTX for psoriasis at risk for hepatic fibrosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
